Key facts
- This page summarizes Mark P. Lappe's Form 4 filing for Inhibrx Biosciences, Inc. (INBX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 16 Sep 2024, 17:12.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Purchase
Purchase
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
The shares were purchased in multiple transactions at prices ranging from $15.00 to $15.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Footnote F2
These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
Footnote F3
The shares were purchased in multiple transactions at prices ranging from $16.70 to $17.695, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Footnote F4
These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.